Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek‐Yeol Ryoo, İrfan Çiçin, Philippe Merle, Yen-Hsun Chen, Joong‐Won Park, Jean-Frederic Blanc, Luigi Bolondi, Heinz‐Josef Klümpen, Stephen L. Chan, Vittorina Zagonel, Tiziana Pressiani, Min-Hee Ryu, Alan P. Venook, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley
New England Journal of Medicine, 2018
Abstract
This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report 2020
- Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance 2023
- Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas 2023
- Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas 2023
- Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas 2023
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 2014
- The National Comprehensive Cancer Network 1998
- Sorafenib in Advanced Hepatocellular Carcinoma 2008
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial 2008
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma 2015